SubjectWell
As the premier Patient Experience Platform, SubjectWell drives predictable clinical trial patient recruitment, improves patient engagement, and enhances retention by optimizing the patient journey from protocol design through study completion. Powered by a combination of creative strategy, global reach, scientific insight, specialized services, and advanced technology, SubjectWell delivers intelligence, predictability and operational efficiency for sponsors, CROs, research sites, and site networks.
Fred Martin
Chief Executive Officer
Dr. Tobias Kruse
Managing Director, Europe
Jeff Evitts
Chief Commercial Officer (CCO)
James Rucki
Executive Director, Commercial Sales
Grant Weaver
Senior Director, Revenue Operations
Camy Moodley
Managing Director
Nick Elvis
Chief Commercial Officer
Shay Staples
Vice President, Customer Success & Operational Excellence
Karl Stubelis
Chief Financial Officer
Steve Ciske
Chief Technology Officer
Frequently Asked Questions about SubjectWell
Who is the CEO of SubjectWell?▼
The current CEO of SubjectWell is Fred Martin, serving as Chief Executive Officer.
How many employees does SubjectWell have?▼
SubjectWell has approximately 51-200 employees. We have mapped 10 people in their organizational chart.
What industry is SubjectWell in?▼
SubjectWell operates in the Pharmaceutical Manufacturing industry and is headquartered in Austin, Texas, United States.
What is SubjectWell's funding stage?▼
SubjectWell is at the seed funding stage.
Who are the key executives at SubjectWell?▼
Key executives at SubjectWell include Fred Martin (Chief Executive Officer), Dr. Tobias Kruse (Managing Director, Europe), Jeff Evitts (Chief Commercial Officer (CCO)), James Rucki (Executive Director, Commercial Sales), Grant Weaver (Senior Director, Revenue Operations).
Where is SubjectWell headquartered?▼
SubjectWell is headquartered in Austin, Texas, United States.
Data sourced from Crustdata | the API for B2B company & people data. Access org charts, headcount, funding, and growth metrics for 60M+ companies.